Crystalpharm Health Limited 08059436 false 2022-09-01 2023-08-31 2023-08-31 The principal activity of the company is retail pharmacy. Digita Accounts Production Advanced 6.30.9574.0 true true 08059436 2022-09-01 2023-08-31 08059436 2023-08-31 08059436 bus:OrdinaryShareClass1 2023-08-31 08059436 core:CurrentFinancialInstruments 2023-08-31 08059436 core:CurrentFinancialInstruments core:WithinOneYear 2023-08-31 08059436 core:Non-currentFinancialInstruments core:AfterOneYear 2023-08-31 08059436 core:ConstructionInProgressAssetsUnderConstruction 2023-08-31 08059436 core:FurnitureFittingsToolsEquipment 2023-08-31 08059436 bus:SmallEntities 2022-09-01 2023-08-31 08059436 bus:AuditExemptWithAccountantsReport 2022-09-01 2023-08-31 08059436 bus:FilletedAccounts 2022-09-01 2023-08-31 08059436 bus:SmallCompaniesRegimeForAccounts 2022-09-01 2023-08-31 08059436 bus:RegisteredOffice 2022-09-01 2023-08-31 08059436 bus:Director2 2022-09-01 2023-08-31 08059436 bus:OrdinaryShareClass1 2022-09-01 2023-08-31 08059436 bus:PrivateLimitedCompanyLtd 2022-09-01 2023-08-31 08059436 core:Goodwill 2022-09-01 2023-08-31 08059436 core:ConstructionInProgressAssetsUnderConstruction 2022-09-01 2023-08-31 08059436 core:FurnitureFittings 2022-09-01 2023-08-31 08059436 core:FurnitureFittingsToolsEquipment 2022-09-01 2023-08-31 08059436 core:OfficeEquipment 2022-09-01 2023-08-31 08059436 countries:EnglandWales 2022-09-01 2023-08-31 08059436 2022-08-31 08059436 core:ConstructionInProgressAssetsUnderConstruction 2022-08-31 08059436 core:FurnitureFittingsToolsEquipment 2022-08-31 08059436 2021-09-01 2022-08-31 08059436 2022-08-31 08059436 bus:OrdinaryShareClass1 2022-08-31 08059436 core:CurrentFinancialInstruments 2022-08-31 08059436 core:CurrentFinancialInstruments core:WithinOneYear 2022-08-31 08059436 core:Non-currentFinancialInstruments core:AfterOneYear 2022-08-31 08059436 core:ConstructionInProgressAssetsUnderConstruction 2022-08-31 08059436 core:FurnitureFittingsToolsEquipment 2022-08-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 08059436

Crystalpharm Health Limited

Unaudited Filleted Abridged Financial Statements

for the Year Ended 31 August 2023

 

Crystalpharm Health Limited

Contents

Company Information

1

Abridged Balance Sheet

2 to 3

Notes to the Unaudited Abridged Financial Statements

4 to 10

 

Crystalpharm Health Limited

Company Information

Director

Mrs S Wahie

Registered office

26 High Street
Rickmansworth
Hertfordshire
WD3 1ER

 

Crystalpharm Health Limited

(Registration number: 08059436)
Abridged Balance Sheet as at 31 August 2023

Note

2023
£

2022
£

Fixed assets

 

Intangible assets

4

240,000

264,000

Tangible assets

5

11,066

3,429

 

251,066

267,429

Current assets

 

Stocks

6

20,250

17,500

Debtors

7

82,149

71,769

Cash at bank and in hand

 

11,487

24,550

 

113,886

113,819

Prepayments and accrued income

 

3,386

3,386

Creditors: Amounts falling due within one year

(148,452)

(165,815)

Net current liabilities

 

(31,180)

(48,610)

Total assets less current liabilities

 

219,886

218,819

Creditors: Amounts falling due after more than one year

-

(8,967)

Accruals and deferred income

 

(9,177)

(13,655)

Net assets

 

210,709

196,197

Capital and reserves

 

Called up share capital

8

100

100

Retained earnings

210,609

196,097

Shareholders' funds

 

210,709

196,197

For the financial year ending 31 August 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

 

Crystalpharm Health Limited

(Registration number: 08059436)
Abridged Balance Sheet as at 31 August 2023

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 28 August 2024
 

.........................................
Mrs S Wahie
Director

 

Crystalpharm Health Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
26 High Street
Rickmansworth
Hertfordshire
WD3 1ER

These financial statements were authorised for issue by the director on 28 August 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Crystalpharm Health Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2023

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixtures and fittings

25% reducing balance

Office equipment

25% reducing balance

Improvements to property

25% reducing balance

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

5% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

 

Crystalpharm Health Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2023

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

 

Crystalpharm Health Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2023

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 7 (2022 - 6).

 

Crystalpharm Health Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2023

4

Intangible assets

Total
£

Cost or valuation

At 1 September 2022

480,000

At 31 August 2023

480,000

Amortisation

At 1 September 2022

216,000

Amortisation charge

24,000

At 31 August 2023

240,000

Carrying amount

At 31 August 2023

240,000

At 31 August 2022

264,000

5

Tangible assets

Furniture, fittings and equipment
 £

Properties under construction
 £

Total
£

Cost or valuation

At 1 September 2022

4,948

-

4,948

Additions

2,519

8,805

11,324

At 31 August 2023

7,467

8,805

16,272

Depreciation

At 1 September 2022

1,519

-

1,519

Charge for the year

1,486

2,201

3,687

At 31 August 2023

3,005

2,201

5,206

Carrying amount

At 31 August 2023

4,462

6,604

11,066

At 31 August 2022

3,429

-

3,429

6

Stocks

2023
£

2022
£

Other inventories

20,250

17,500

 

Crystalpharm Health Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2023

7

Debtors

Debtors includes £Nil (2022 - £Nil) due after more than one year.

8

Share capital

Allotted, called up and fully paid shares

2023

2022

No.

£

No.

£

Ordinary shares of £1 each

100

100

100

100

       

9

Dividends

2023

2022

£

£

 

 

10

Related party transactions

At the year-end, the balance owed by the company to the director was £49,009 (2022 £41,276).

During the year, dividends declared amounted to £24,000 (2022: £24,000).

 

Crystalpharm Health Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 August 2023

Director's remuneration

The director's remuneration for the year was as follows:

2023
£

2022
£

Remuneration

12,000

23,917

Contributions paid to money purchase schemes

173

531

12,173

24,448